Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2013

01-04-2013 | Review

The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker

Authors: Michael L Salmans, Fang Zhao, Bogi Andersen

Published in: Breast Cancer Research | Issue 2/2013

Login to get access

Abstract

Initially discovered as an estrogen-responsive gene in breast cancer cell lines, anterior gradient 2 (AGR2) is a developmentally regulated gene belonging to the protein disulfide isomerase (PDI) gene family. Developmentally, AGR2 is expressed in the mammary gland in an estrogen-dependent manner, and AGR2 knockout and overexpression mouse models indicate that the gene promotes lobuloalveolar development by stimulating cell proliferation. Although AGR2 overexpression alone seems insufficient for breast tumorigenesis in mice, several lines of investigations suggest that AGR2 promotes breast tumorigenesis. Overexpression of AGR2 in several breast cancer cell lines increases cell survival in clonogenic assays and cell proliferation, whereas AGR2 loss of function leads to decreased cell cycle progression and cell death. In addition, AGR2 was shown to promote metastasis of breast epithelial cells in an in vivo metastasis assay. As a PDI, AGR2 is thought to be involved in the unfolded protein response that alleviates endoplasmic reticulum stress. Since cancer has to overcome proteotoxic stress due to excess protein production, AGR2 may be one of many pro-survival factors recruited to assist in protein folding or degradation or both. When AGR2 is secreted, it plays a role in cellular adhesion and dissemination of metastatic tumor cells. In breast cancer, AGR2 expression is associated with estrogen receptor (ER)-positive tumors; its overexpression is a predictor of poor prognosis. The AGR2 gene is directly targeted by ER-alpha, which is preferentially bound in tumors with poor outcome. Whereas aromatase inhibitor therapy decreases AGR2 expression, tamoxifen acts as an agonist of AGR2 expression in ER-positive tumors, perhaps contributing to tamoxifen resistance. AGR2 is also overexpressed in a subset of ER-negative tumors. Furthermore, AGR2 expression is associated with the dissemination of metastatic breast cancer cells and can be used as a marker to identify circulating tumor cells and metastatic cells in sentinel lymph nodes. In conclusion, AGR2 is a promising drug target in breast cancer and may serve as a useful prognostic indicator as well as a marker of breast cancer metastasis.
Appendix
Available only for authorised users
Literature
1.
Kuang WW, Thompson DA, Hoch RV, Weigel RJ: Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line. Nucleic Acids Res. 1998, 26: 1116-1123. 10.1093/nar/26.4.1116.CrossRefPubMedPubMedCentral
2.
Thompson DA, Weigel RJ: hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem Biophys Res Commun. 1998, 251: 111-116. 10.1006/bbrc.1998.9440.CrossRefPubMed
3.
Fletcher GC, Patel S, Tyson K, Adam PJ, Schenker M, Loader JA, Daviet L, Legrain P, Parekh R, Harris AL, Terrett JA: hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer. 2003, 88: 579-585. 10.1038/sj.bjc.6600740.CrossRefPubMedPubMedCentral
4.
Maresh E L, Mah V, Alavi M, Horvath S, Bagryanova L, Liebeskind ES, Knutzen LA, Zhou Y, Chia D, Liu AY, Goodglick L: Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer. 2010, 10: 680-10.1186/1471-2407-10-680.CrossRefPubMedPubMedCentral
5.
Park K, Chung YJ, So H, Kim K, Park J, Oh M, Jo M, Choi K, Lee EJ, Choi YL, Song SY, Bae DS, Kim BG, Lee JH: AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med. 2011, 43: 91-100. 10.3858/emm.2011.43.2.011.CrossRefPubMedPubMedCentral
6.
Pizzi M, Fassan M, Balistreri M, Galligioni A, Rea F, Rugge M: Anterior gradient 2 overexpression in lung adenocarcinoma. Appl Immunohistochem Mol Morphol. 2012, 20: 31-36. 10.1097/PAI.0b013e3182233f9f.CrossRefPubMed
7.
Ramachandran V, Arumugam T, Wang H, Logsdon CD: Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res. 2008, 68: 7811-7818. 10.1158/0008-5472.CAN-08-1320.CrossRefPubMedPubMedCentral
8.
Wang Z, Hao Y, Lowe AW: The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res. 2008, 68: 492-497. 10.1158/0008-5472.CAN-07-2930.CrossRefPubMed
9.
Fritzsch e FR, Dahl E, Pahl S, Burkhardt M, Luo J, Mayordomo E, Gansukh T, Dankof A, Knuechel R, Denkert C, Winzer KJ, Dietel M, Kristiansen G: Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res. 2006, 12: 1728-1734. 10.1158/1078-0432.CCR-05-2057.CrossRef
10.
Kim HS, Kang SH, Park CH, Yang WI, Jeung HC, Chung HC, Roh JK, Ahn JB, Kim NK, Min BS, Rha SY: Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. Oncol Rep. 2011, 25: 717-727.PubMed
11.
Hrstka R, Nenutil R, Fourtouna A, Maslon MM, Naughton C, Langdon S, Murray E, Larionov A, Petrakova K, Muller P, Dixon MJ, Hupp TR, Vojtesek B: The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene. 2010, 29: 4838-4847. 10.1038/onc.2010.228.CrossRefPubMed
12.
Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, Janatpour MJ: Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Res. 2010, 12: R32-10.1186/bcr2586.CrossRefPubMedPubMedCentral
13.
Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R: Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res. 2005, 65: 3796-3805. 10.1158/0008-5472.CAN-04-3823.CrossRefPubMed
14.
Norris AM, Gore A, Balboni A, Young A, Longnecker DS, Korc M: AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia. Oncogene. 2012, 10.1038/onc.2012.394. doi: 10.1038
15.
Higa A, Mulot A, Delom F, Bouchecareilh M, Nguyên DT, Boismenu D, Wise MJ, Chevet E: Role of pro-oncogenic protein disulfide isomerase (PDI) family member anterior gradient 2 (AGR2) in the control of endoplasmic reticulum homeostasis. J Biol Chem. 2011, 286: 44855-44868. 10.1074/jbc.M111.275529.CrossRefPubMedPubMedCentral
16.
Benham AM: The protein disulfide isomerase family: key players in health and disease. Antioxid Redox Signal. 2012, 16: 781-789. 10.1089/ars.2011.4439.CrossRefPubMed
17.
Aberger F, Weidinger G, Grunz H, Richter K: Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2. Mech Dev. 1998, 72: 115-130. 10.1016/S0925-4773(98)00021-5.CrossRefPubMed
18.
Adam PJ, Boyd R, Tyson KL, Fletcher GC, Stamps A, Hudson L, Poyser HR, Redpath N, Griffiths M, Steers G, Harris AL, Patel S, Berry J, Loader JA, Townsend RR, Daviet L, Legrain P, Parekh R, Terrett JA: Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem. 2003, 278: 6482-6489. 10.1074/jbc.M210184200.CrossRefPubMed
19.
Petek E, Windpassinger C, Egger H, Kroisel PM, Wagner K: Localization of the human anterior gradient-2 gene (AGR2) to chromosome band 7p21.3 by radiation hybrid mapping and fluorescencein situ hybridisation. Cytogenet Cell Genet. 2000, 89: 141-142. 10.1159/000015594.CrossRefPubMed
20.
Verma S, Salmans ML, Geyfman M, Wang H, Yu Z, Lu Z, Zhao F, Lipkin SM, Andersen B: The estrogen-responsive Agr2 gene regulates mammary epithelial proliferation and facilitates lobuloalveolar development. Dev Biol. 2012, 369: 249-260. 10.1016/j.ydbio.2012.06.030.CrossRefPubMedPubMedCentral
21.
Gray TA, MacLaine NJ, Michie CO, Bouchalova P, Murray E, Howie J, Hrstka R, Maslon MM, Nenutil R, Vojtesek B, Langdon S, Hayward L, Gourley C, Hupp TR: Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models. J Immunol Methods. 2012, 378: 20-32. 10.1016/j.jim.2012.01.013.CrossRefPubMed
22.
Bu H, S chweiger MR, Manke T, Wunderlich A, Timmermann B, Kerick M, Pasqualini L, Shehu E, Fuchsberger C, Cato AC, Klocker H: Anterior gradient 2 and 3 - two prototype androgen-responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells. FEBS J. 2013, 280: 1249-1266. 10.1111/febs.12118.CrossRefPubMed
23.
Fullwoo d MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S, Ho A, Mei PH, Chew EG, Huang PY, Welboren WJ, Han Y, Ooi HS, Ariyaratne PN, Vega VB, Luo Y, Tan PY, Choy PY, Wansa KD, Zhao B, Lim KS, Leow SC, Yow JS, Joseph R, Li H, Desai KV, Thomsen JS, Lee YK, Karuturi RK, Herve T, Bourque G, Stunnenberg HG, Ruan X, Cacheux-Rataboul V, Sung WK, Liu ET, Wei CL, Cheung E, Ruan Y: An oestrogen-receptor-alpha-bound human chromatin interactome. Nature. 2009, 462: 58-64. 10.1038/nature08497.CrossRef
24.
Persson S, Rosenquist M, Knoblach B, Khosravi-Far R, Sommarin M, Michalak M: Diversity of the protein disulfide isomerase family: identification of breast tumor induced Hag2 and Hag3 as novel members of the protein family. Mol Phylogenet Evol. 2005, 36: 734-740. 10.1016/j.ympev.2005.04.002.CrossRefPubMed
25.
Innes H E, Liu D, Barraclough R, Davies MP, O'Neill PA, Platt-Higgins A, de Silva Rudland S, Sibson DR, Rudland PS: Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer. 2006, 94: 1057-1065. 10.1038/sj.bjc.6603065.CrossRefPubMedPubMedCentral
26.
Barraclough DL, Platt-Higgins A, de Silva Rudland S, Barraclough R, Winstanley J, West CR, Rudland PS: The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol. 2009, 175: 1848-1857. 10.2353/ajpath.2009.090246.CrossRefPubMedPubMedCentral
27.
Zweitzi g DR, Smirnov DA, Connelly MC, Terstappen LW, O'Hara SM, Moran E: Physiological stress induces the metastasis marker AGR2 in breast cancer cells. Mol Cell Biochem. 2007, 306: 255-260. 10.1007/s11010-007-9562-y.CrossRef
28.
Perou C M, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed
29.
van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.CrossRefPubMed
30.
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12: R68-10.1186/bcr2635.CrossRefPubMedPubMedCentral
31.
Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bièche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de Thé H, Theillet C: A refined molecular taxonomy of breast cancer. Oncogene. 2011, 31: 1196-1206.CrossRefPubMedPubMedCentral
32.
Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB: Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer. 2006, 13: 617-628. 10.1677/erc.1.01165.CrossRefPubMed
33.
Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali H R, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS: Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 2012, 481: 389-393.PubMedPubMedCentral
34.
Welboren W-J, Driel MAv, Janssen-Megens EM, Heeringen SJv, Sweep FC, Span PN, Stunnenberg HG: ChIP-Seq of ER|[alpha]| and RNA polymerase II defines genes differentially responding to ligands. EMBO J. 2009, 28: 1418-1428. 10.1038/emboj.2009.88.CrossRefPubMedPubMedCentral
35.
Zhang JS, Gong A, Cheville JC, Smith DI, Young CY: AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer. 2005, 43: 249-259. 10.1002/gcc.20188.CrossRefPubMed
36.
Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M: Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res. 2007, 9: R37-10.1186/bcr1732.CrossRefPubMedPubMedCentral
37.
Hengel SM, Murray E, Langdon S, Hayward L, O'Donoghue J, Panchaud A, Hupp T, Goodlett DR: Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance. J Proteome Res. 2011, 10: 4567-4578. 10.1021/pr2004117.CrossRefPubMedPubMedCentral
38.
Coser KR, Wittner BS, Rosenthal NF, Collins SC, Melas A, Smith SL, Mahoney CJ, Shioda K, Isselbacher KJ, Ramaswamy S, Shioda T: Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci USA. 2009, 106: 14536-14541. 10.1073/pnas.0907560106.CrossRefPubMedPubMedCentral
39.
Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar T C, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003, 22: 7316-7339. 10.1038/sj.onc.1206937.CrossRefPubMed
40.
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN: Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012, 367: 435-444. 10.1056/NEJMoa1201622.CrossRefPubMedPubMedCentral
41.
Tveito S, Andersen K, Karesen R, Fodstad Ø: Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles. Breast Cancer Res. 2011, 13: R75-10.1186/bcr2922.CrossRefPubMedPubMedCentral
42.
Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pie nta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, Connelly MC, Terstappen LW, O'Hara SM: Global gene expression profiling of circulating tumor cells. Cancer Res. 2005, 65: 4993-4997. 10.1158/0008-5472.CAN-04-4330.CrossRefPubMed
43.
da Costa A, Lenze D, Hummel M, Kohn B, Gruber AD, Klopfleis ch R: Identification of six potential markers for the detection of circulating canine mammary tumour cells in the peripheral blood identified by microarray analysis. J Comp Pathol. 2012, 146: 143-151. 10.1016/j.jcpa.2011.06.004.CrossRefPubMed
44.
Marín-Aguilera M, Mengual L, Ribal MJ, Ars E, Ríos J, Gázquez C, Villavicencio H, Alcaraz A: Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer. Urology. 2012, 79: 240.e249-215. 10.1016/j.urology.2011.09.006.CrossRef
45.
Valladares-Ayerbes M, Díaz-Prado S, Reboredo M, Medina V, Igle sias-Díaz P, Lorenzo-Patiño MJ, Campelo RG, Haz M, Santamarina I, Antón-Aparicio LM: Bioinformatics approach to mRNA markers discovery for detection of circulating tumor cells in patients with gastrointestinal cancer. Cancer Detect Prev. 2008, 32: 236-250. 10.1016/j.cdp.2008.08.002.CrossRefPubMed
46.
Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009, 136: 823-837. 10.1016/j.cell.2009.02.024.CrossRefPubMedPubMedCentral
47.
Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR, Pointer JN, Gruber SB, Su LD, Nikiforov MA, Kaufman RJ, Bastian BC, Soengas MS: Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol. 2006, 8: 1053-1063. 10.1038/ncb1471.CrossRefPubMed
48.
Whitesell L, Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005, 5: 761-772. 10.1038/nrc1716.CrossRefPubMed
49.
Simpson NE, Lambert WM, Watkins R, Giashuddin S, Huang SJ, Oxelmar k E, Arju R, Hochman T, Goldberg JD, Schneider RJ, Reiz LF, Soares FA, Logan SK, Garabedian MJ: High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance. Cancer Res. 2010, 70: 8446-8456. 10.1158/0008-5472.CAN-10-1590.CrossRefPubMedPubMedCentral
50.
Sevier CS, Kaiser CA: Formation and transfer of disulphide bonds in living cells. Nat Rev Mol Cell Biol. 2002, 3: 836-847. 10.1038/nrm954.CrossRefPubMed
51.
Zhao F, Edwards R, Dizon D, Afrasiabi K, Mastroianni JR, Geyfman M, Ouellette AJ, Andersen B, Lipkin SM: Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress in Agr2-/- mice. Dev Biol. 2010, 338: 270-279. 10.1016/j.ydbio.2009.12.008.CrossRefPubMed
52.
Kang K, Park B, Oh C, Cho K, Ahn K: A role for protein disulfide isomerase in the early folding and assembly of MHC class I molecules. Antioxid Redox Signal. 2009, 11: 2553-2561. 10.1089/ars.2009.2465.CrossRefPubMed
53.
Cho K, Cho S, Lee SO, Oh C, Kang K, Ryoo J, Lee S, Kang S, Ahn K: Redoxregulated peptide transfer from the transporter associated with antigen processing to major histocompatibility complex class I molecules by protein disulfide isomerase. Antioxid Redox Signal. 2011, 15: 621-633. 10.1089/ars.2010.3756.CrossRefPubMed
54.
Lee HJ, Hong CY, Kim MH, Lee YK, Nguyen-Pham TN, Park BC, Yang DH, Chung IJ, Kim HJ, Lee JJ: In vitro induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer. Exp Mol Med. 2012, 44: 60-67. 10.3858/emm.2012.44.1.006.CrossRefPubMed
55.
Dumartin L, Whiteman HJ, Weeks ME, Hariharan D, Dmitrovic B, Iacobuzio-Donahue CA, Brentnall TA, Bronner MP, Feakins RM, Timms JF, Brennan C, Lemoine NR, Crnogorac-Jurcevic T: AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res. 2011, 71: 7091-7102. 10.1158/0008-5472.CAN-11-1367.CrossRefPubMedPubMedCentral
56.
Park SW, Zhen G, Verhaeghe C, Nakagami Y, Nguyenvu LT, Barczak AJ, Killeen N, Erle DJ: The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc Natl Acad Sci USA. 2009, 106: 6950-6955. 10.1073/pnas.0808722106.CrossRefPubMedPubMedCentral
57.
58.
Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK: Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta. 2011, 1815: 224-240.PubMedPubMedCentral
59.
Wang J, Jarrett J, Huang CC, Satcher RL, Levenson AS: Identification of estrogen-responsive genes involved in breast cancer metastases to the bone. Clin Exp Metastasis. 2007, 24: 411-422. 10.1007/s10585-007-9078-6.CrossRefPubMed
60.
Wei X, Xu H, Kufe D: MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell. 2006, 21: 295-305. 10.1016/j.molcel.2005.11.030.CrossRefPubMed
61.
Schroeder BW, Verhaeghe C, Park SW, Nguyenvu LT, Huang X, Zhen G, Erle DJ: AGR2 is induced in asthma and promotes allergen-induced mucin overproduction. Am J Respir Cell Mol Biol. 2012, 47: 178-185. 10.1165/rcmb.2011-0421OC.CrossRefPubMedPubMedCentral
62.
Zhang Y, Ali TZ, Zhou H, D'Souza DR, Lu Y, Jaffe J, Liu Z, Passaniti A, Hamburger AW: ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer. Cancer Res. 2010, 70: 240-248. 10.1158/0008-5472.CAN-09-2904.CrossRefPubMedPubMedCentral
63.
Maslon MM, Hrstka R, Vojtesek B, Hupp TR: A divergent substrate-binding loop within the pro-oncogenic protein anterior gradient-2 forms a docking site for Reptin. J Mol Biol. 2010, 404: 418-438. 10.1016/j.jmb.2010.09.035.CrossRefPubMed
64.
Kim JH, Choi HJ, Kim B, Kim MH, Lee JM, Kim IS, Lee MH, Choi SJ, Kim KI, Kim SI, Chung CH, Baek SH: Roles of sumoylation of a reptin chromatin-remodelling complex in cancer metastasis. Nat Cell Biol. 2006, 8: 631-639. 10.1038/ncb1415.CrossRefPubMed
65.
Venteicher AS, Meng Z, Mason PJ, Veenstra TD, Artandi SE: Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell. 2008, 132: 945-957. 10.1016/j.cell.2008.01.019.CrossRefPubMedPubMedCentral
66.
Rashid S, Pilecka I, Torun A, Olchowik M, Bielinska B, Miaczynska M: Endosomal adaptor proteins APPL1 and APPL2 are novel activators of beta-catenin/TCF-mediated transcription. J Biol Chem. 2009, 284: 18115-18128. 10.1074/jbc.M109.007237.CrossRefPubMedPubMedCentral
67.
Qi D, Jin H, Lilja T, Mannervik M: Drosophila Reptin and other TIP 60 complex components promote generation of silent chromatin. Genetics. 2006, 174: 241-251. 10.1534/genetics.106.059980.CrossRefPubMedPubMedCentral
68.
Bellosta P, Hulf T, Balla Diop S, Usseglio F, Pradel J, Aragnol D, Gallant P: Myc interacts genetically with Tip48/Reptin and Tip49/Pontin to control growth and proliferation during Drosophila development. Proc Natl Acad Sci USA. 2005, 102: 11799-11804. 10.1073/pnas.0408945102.CrossRefPubMedPubMedCentral
69.
Dong A, Gupta A, Pai RK, Tun M, Lowe AW: The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation. J Biol Chem. 2011, 286: 18301-18310. 10.1074/jbc.M110.215707.CrossRefPubMedPubMedCentral
70.
Ambolet-Camoit A, Bui LC, Pierre S, Chevallier A, Marchand A, Coumoul X, Garlatti M, Andreau K, Barouki R, Aggerbeck M: 2,3,7,8-tetrachlorodibenzo-p-dioxin counteracts the p53 response to a genotoxicant by upregulating expression of the metastasis marker agr2 in the hepatocarcinoma cell line HepG2. Toxicol Sci. 2010, 115: 501-512. 10.1093/toxsci/kfq082.CrossRefPubMed
71.
Pohler E, Craig AL, Cotton J, Lawrie L, Dillon JF, Ross P, Kernohan N, Hupp TR: The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics. 2004, 3: 534-547. 10.1074/mcp.M300089-MCP200.CrossRefPubMed
72.
Imamura T, Hikita A, Inoue Y: The roles of TGF-β signaling in carcinogenesis and breast cancer metastasis. Breast Cancer. 2012, 19: 118-124. 10.1007/s12282-011-0321-2.CrossRefPubMed
Metadata
Title
The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker
Authors
Michael L Salmans
Fang Zhao
Bogi Andersen
Publication date
01-04-2013
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3408

Other articles of this Issue 2/2013

Breast Cancer Research 2/2013 Go to the issue

Research article

HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma

Research article

Embryonic mammary signature subsets are activated in Brca1 -/- and basal-like breast cancers

Research article

Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer

Research article

Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer

Research article

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs

Research article

Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits